-
Valeant's Debt In 2020 'May Be Too High A Hurdle'
Wednesday, June 8, 2016 - 8:39am | 417Read More...Valeant Pharmaceuticals Intl Inc (NYSE: VRX) filed its 10-Q for 1Q16 on July 7. Wells Fargo’s David Maris maintained an Underperform rating for the company, while reducing its valuation range from $25-$30 to $17-$22. The analyst expressed concern regarding the deterioration in Valeant...
-
Wells Fargo's Analyst Discusses Valeant's 'Apology Tour'
Wednesday, April 27, 2016 - 2:58pm | 346Read More...David Maris is an analyst at Wells Fargo that initiated coverage of Valeant Pharmaceuticals Intl Inc (NYSE: VRX) with a Sell rating back in February. On Wednesday, he was a guest on CNBC's Halftime Report segment to discuss his views on the company. Maris began by saying that appointing Joe Pappa...
-
Valeant's Default Notice Should Keep Investors On Sidelines: Wells Fargo Keeps Underperform Rating
Wednesday, April 13, 2016 - 8:49am | 297Read More...Valeant Pharmaceuticals Intl Inc (NYSE: VRX) has received a default notice from holders of its 5.5 percent Notes due 2023, due to the delay in filing its 2015 10-K. Wells Fargo’s David Maris maintained an Underperform rating for the company, saying that equity holders were in a “poor...
-
Left: I No Longer Have Valeant Short
Wednesday, March 2, 2016 - 3:14pm | 295Read More...Short-seller Andrew Left of Citron Research said he has no position in Valeant Pharmaceuticals Intl Inc (NYSE: VRX), according to an interview with CNBC. "Right now the stock is uninvestable. I wouldn't be short Valeant, I wouldn't be long Valeant. Right now there are too many black dots...
-
Valeant Gets Closer To Left's $50 Target After New Accounting Fears
Monday, February 22, 2016 - 9:59pm | 379Read More...Valeant Pharmaceuticals Intl Inc. (NYSE: VRX) shares plunged nearly 9 percent in Monday's after-hours trading session following word the company may have to restate financial results, before recovering slightly. The potential restatement, according to sources, would come on the heels of a...
-
UPDATE: Valeant Plunges 7% After Bearish Wells Fargo Report
Friday, February 19, 2016 - 12:27pm | 252Read More...Valeant's stock has reacted to Wells Fargo's latest analysis of the company, seen below on Benzinga Pro. Shares of Valeant Pharmaceuticals Intl Inc (NYSE: VRX) opened for trading on Friday at $90.48 and moved lower throughout the morning trading session. After nearly 2 full hours of...
-
UPDATE: The Problem With Valeant's Guidance, According To Wells Fargo
Friday, February 19, 2016 - 10:10am | 413Read More...Wells Fargo’s David Maris mentioned that there were unanswered questions related to the guidance issued by Valeant Pharmaceuticals Intl Inc (NYSE: VRX). He explained the discrepancy between management’s updated guidance and the previous statements about the impact of Philidor....
-
Valeant Has 42% Downside And Too Many Questions, Wells Fargo Warns
Friday, February 19, 2016 - 9:49am | 271Read More...Wells Fargo’s David Maris initiated coverage of Valeant Pharmaceuticals Intl Inc (NYSE: VRX) with an Underperform rating and a valuation range of $65-$68. He mentioned that the valuation range implies a potential downside of 42 percent from the current share price. Analyst David Maris...
-
Top Takeaways From BMO's Specialty Pharma Day
Wednesday, July 1, 2015 - 1:13pm | 583Read More...In a report published Wednesday, BMO Capital Markets analyst David Maris discussed key takeaways from a day of meetings with several specialty pharmaceutical companies. Below are some of the highlights of notable presentations. Allergan PLC (NYSE: AGN): The company is planning to work...
-
Is Teva A Better Target For Mylan Than Perrigo? 2 Analysts Share Their Thoughts
Wednesday, April 8, 2015 - 4:00pm | 447Read More...Mylan NV (NASDAQ: MYL) said Wednesday it has offered to acquire rival Perrigo Company (NYSE: PRGO) for $28.9 billion or $205 a share Umer Raffat of Evercore ISI had a chance to chat with Mylan’s management recently. The Mylan-Perrigo accretion “looks something like 10-15%...
-
Analyst Offers Insight on Favorable FDA Ruling for Teva Pharma
Monday, March 31, 2014 - 4:03pm | 131Read More...Shares of Teva Pharmaceutical (NYSE: TEVA) are up 6.66 percent to $52.74 on news that the company has received a U.S. Supreme Court hearing on generic Copaxone delay. The news will “bolster investor confidence that a generic will not be on the market in May 2014,” BMO Capital analyst David Maris...
-
UPDATE: BMO Capital Markets Reiterates on Teva Pharmaceutical Industries Ltd. Following Announcement of CEO Resignation
Thursday, October 31, 2013 - 11:21am | 149Read More...In a report published Thursday, BMO Capital Markets analyst David Maris reiterated an Outperform rating on Teva Pharmaceutical Industries Ltd. (NYSE: TEVA), but lowered the price target from $49.00 to $44.00. In the report, BMO Capital Markets noted, “In surprising news today, Teva announced the...
-
UPDATE: BMO Capital Markets Upgrades Forest Laboratories as Underperformance is Unlikely While Street Awaits New Plan
Friday, October 25, 2013 - 10:44am | 128Read More...In a report published Friday, BMO Capital Markets analyst David Maris upgraded the rating on Forest Laboratories (NYSE: FRX) from Underperform to Market Perform, and raised the price target from $27.00 to $33.00. In the report, BMO Capital Markets noted, “Forest reported its fiscal second-quarter...
